Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 837

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 837
---
 terms as follows: 1.Upon approval by the Company’s Board of Directors, Prof. Revel shall provide the Company with a loan in the amount of NIS 1 million (USD $269 thousand). The loan bears no interest and is not linked to any index and unsecured. 2.The loan shall remain in effect for a period of one year, which shall automatically renew for consecutive 12 -monthperiods, unless the parties agree to an earlier repayment in writing, at least 30 days prior to the end of the applicable term. 3.Subject to the approval of the Company’s general meeting of shareholders, the loan shall be converted into Company shares, at the earlier of: (i) a date close to the closing date of the Company’s merger with NLS, if and when completed, at the market price as that time (calculated as the average share price of the 14 trading days prior to the conversion date); or (ii) alternatively, if the Company conducts an equity financing round in proximity to the completion of the merger, any other equity financing. Annex G-45 Annex H VOTE ON INTERNET Go to http://www.vstocktransfer.com/proxy Click on Proxy Voter Login and log-on using the below control number. Voting will be open until 11:59 p.m. (Eastern Time) August 20, CONTROL 

# VOTE BY EMAIL Mark, sign and date your proxy card and send it to vote@vstocktransfer.com. SPECIMEN 1 MAIN STREET ANYWHERE PA 99999-9999 VOTE BY MAIL Mark, sign and date your proxy card and return it in the envelope we have provided. Please Vote, Sign, Date and Return Promptly in the Enclosed Envelope. Extraordinary Meeting of Shareholders Proxy Card - NLS Pharmaceutics Ltd. DETACH PROXY CARD HERE TO VOTE BY MAIL The Board of Directors recommends a vote “FOR” all listed Proposals. 1. Approval of the Merger Agreement on an advisory basis The board proposes to approve the Merger Agreement, that the Company has entered into on 4 November 2024 according to which it will merge with Kadimastem, in the sense of an advisory vote. 2. Par Value Reduction, Reverse split and Contribution in Kind The board proposes (i) to reduce the share capital and the participation capital by a reduction of the respective nominal values, (ii) to increase the share capital and the participation capital, (iii) to implement a reverse share